Mutant proteins as cancer-specific biomarkers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 6, 2011, Pages 2444-2449

  Wang, Qing ^a,b   Chaerkady, Raghothama ^c,e   Wu, Jian ^a,b   Hwang, Hee Jung ^a,b   Papadopoulos, Nick ^a,b   Kopelovich, Levy ^f   Maitra, Anirban ^d   Matthaei, Hanno ^d   Eshleman, James R ^d   Hruban, Ralph H ^d   Kinzler, Kenneth W ^a,b   Pandey, Akhilesh ^c,d   Vogelstein, Bert ^a,b  

^a Ludwig Center for Cancer Genetics and Therapeutics   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e Institute of Bioinformatics   (India)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Companion diagnostics; Genetic diagnosis; Genetics; Pancreatic cancer; Proteomics

Indexed keywords

H RAS PROTEIN; K RAS PROTEIN; MUTANT PROTEIN; RAS PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANCER CELL; CELL LINE; COLORECTAL TUMOR; CONTROLLED STUDY; CYST FLUID; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; PANCREAS TUMOR; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; SOMATIC MUTATION;

CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MUTANT PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952284442     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1019203108     Document Type: Article

References (37)

1. Wood LD, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113. (Pubitemid 350134889)
2. Jones S, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806.
3. Parsons DW, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
4. Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458:719-724.
5. Bignell GR, et al. (2010) Signatures of mutation and selection in the cancer genome. Nature 463:893-898.
6. Bozic I, et al. (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 107:18545-18550.
7. Mann M, Kelleher NL (2008) Precision proteomics: The case for high resolution and high mass accuracy. Proc Natl Acad Sci USA 105:18132-18138.
8. Ciordia S, de Los Ríos V, Albar JP (2006) Contributions of advanced proteomics technologies to cancer diagnosis. Clin Transl Oncol 8:566-580.
9. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP (2003) Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA 100:6940-6945. (Pubitemid 36706372)
10. Old WM, et al. (2005) Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 4:1487-1502. (Pubitemid 41555475)
11. Ong SE, et al. (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1:376-386.
12. Schnölzer M, Jedrzejewski P, Lehmann WD (1996) Protease-catalyzed incorporation of 18O into peptide fragments and its application for protein sequencing by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. Electrophoresis 17:945-953.
13. Wiese S, Reidegeld KA, Meyer HE, Warscheid B (2007) Protein labeling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research. Proteomics 7:340-350. (Pubitemid 46293976)
14. Tabb DL, et al. (2010) Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res 9:761-776.
15. Little DP, Braun A, O'Donnell MJ, Köster H (1997) Mass spectrometry from miniaturized arrays for full comparative DNA analysis. Nat Med 3:1413-1416. (Pubitemid 28011046)
16. Murray KK (1996) DNA sequencing by mass spectrometry. J Mass Spectrom 31:1203-1215.
17. Connors LH, Yamashita T, Yazaki M, Skinner M, Benson MD (2004) A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy. Amyloid 11:61-66. (Pubitemid 38680241)
18. Lim A, et al. (2002) Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis. Anal Chem 74:741-751. (Pubitemid 34160539)
19. Nepomuceno AI, Mason CJ, Muddiman DC, Bergen HR, 3rd, Zeldenrust SR (2004) Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization fourier-transform ion-cyclotron-resonance mass spectrometry. Clin Chem 50:1535-1543. (Pubitemid 39121221)
20. Rosenzweig M, et al. (2007) A new transthyretin variant (Glu61Gly) associated with cardiomyopathy. Amyloid 14:65-71. (Pubitemid 46491165)
21. Bunger MK, et al. (2007) Detection and validation of non-synonymous coding SNPs from orthogonal analysis of shotgun proteomics data. J Proteome Res 6:2331-2340. (Pubitemid 46985121)
22. Muñoz J, et al. (2008) Mass spectrometric characterization of mitochondrial complex I NDUFA10 variants. Proteomics 8:1898-1908. (Pubitemid 351678291)
23. Hanke S, Besir H, Oesterhelt D, Mann M (2008) Absolute SILAC for accurate quantitation of proteins in complex mixtures down to the attomole level. J Proteome Res 7:1118-1130.
24. Tu C, et al. (2010) Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 9:4982-4991.
25. Anderson NL, et al. (2004) Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 3:235-244. (Pubitemid 38500990)
26. Whiteaker JR, et al. (2007) Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem 362:44-54. (Pubitemid 46198803)
27. Capon DJ, et al. (1983) Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304:507-513. (Pubitemid 13026946)
28. Picotti P, et al. (2010) High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods 7:43-46.
29. Kostiainen R, Kotiaho T, Kuuranne T, Auriola S (2003) Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J Mass Spectrom 38:357-372. (Pubitemid 36582213)
30. Addona TA, et al. (2009) Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 27:633-641.
31. Anderson L, Hunter CL (2006) Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 5:573-588.
32. Rajagopalan H, et al. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934. (Pubitemid 34976022)
33. Megibow AJ (2008) Update in imaging of cystic pancreatic masses for gastroenterologists. Clin Gastroenterol Hepatol 6:1194-1197.
34. Anderson MA, Kwon RS, Scheiman JM (2009) PANDA cyst-fluid analysis: Eats, shoots and leaves? Gastrointest Endosc 69:1103-1105.
35. Millar BC, Xu J, Moore JE (2002) Risk assessment models and contamination management: Implications for broad-range ribosomal DNA PCR as a diagnostic tool in medical bacteriology. J Clin Microbiol 40:1575-1580. (Pubitemid 34493122)
36. Jaffee EM, et al. (1998) Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 4:194-203.
37. MacLean B, et al. (2010) Skyline: An open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26:966-968.